Pacific Horizon Ventures

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Koronis Pharmaceuticals is a biotechnology company focused on developing antiviral therapeutics through its innovative mechanism known as Viral Decay Acceleration (VDA). Founded in 1998 and headquartered in Seattle, Washington, the company’s lead product candidate, KP-1461, targets the treatment of human immunodeficiency virus (HIV). In addition to HIV, Koronis is also advancing therapies for hepatitis C and respiratory syncytial virus (RSV). The company's research aims to enhance recovery for patients suffering from these diseases while minimizing complications and side effects associated with traditional antiviral treatments.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at advancing ophthalmic care. The company focuses on Interventional Ophthalmology, a novel field that employs microcatheter-based therapies to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enhancing treatment options for ophthalmologists. Additionally, iScience Interventional provides medical devices for canaloplasty procedures, further contributing to the management of ophthalmic diseases. Through these innovations, the company aims to improve patient outcomes and expand the capabilities of ocular therapies.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

Proxim Wireless Corporation specializes in high-speed wireless communication technologies, offering a range of products for Wi-Fi, point-to-point, and point-to-multipoint 4G networks. Their solutions are designed for various applications, including wireless Internet, video surveillance, and backhaul services. Proxim's product lineup includes wireless broadband systems, LAN access products, and network controllers, catering to diverse sectors such as transportation, healthcare, government, and education. The company focuses on delivering secure and scalable wireless solutions, enabling customers to provide voice, video, data, and mobility services. Proxim serves a global clientele through online retailers, distributors, value-added resellers, system integrators, and original equipment manufacturers. Founded in 1982 and headquartered in San Jose, California, Proxim Wireless operates as a subsidiary of SRA Holdings, Inc.